BR0113675A - Compostos de anti-tumor tricìclicos sendo inibidores de proteìna farnesil transferase - Google Patents
Compostos de anti-tumor tricìclicos sendo inibidores de proteìna farnesil transferaseInfo
- Publication number
- BR0113675A BR0113675A BR0113675-5A BR0113675A BR0113675A BR 0113675 A BR0113675 A BR 0113675A BR 0113675 A BR0113675 A BR 0113675A BR 0113675 A BR0113675 A BR 0113675A
- Authority
- BR
- Brazil
- Prior art keywords
- tricyclic
- compounds
- farnesyl transferase
- protein inhibitors
- transferase protein
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 102000007317 Farnesyltranstransferase Human genes 0.000 title 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229950008696 farnesil Drugs 0.000 abstract 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000003558 transferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918300P | 2000-08-30 | 2000-08-30 | |
| PCT/US2001/026792 WO2002018368A1 (en) | 2000-08-30 | 2001-08-28 | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0113675A true BR0113675A (pt) | 2003-06-24 |
Family
ID=22860141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0113675-5A BR0113675A (pt) | 2000-08-30 | 2001-08-28 | Compostos de anti-tumor tricìclicos sendo inibidores de proteìna farnesil transferase |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020198216A1 (OSRAM) |
| EP (1) | EP1313725B1 (OSRAM) |
| JP (1) | JP2004513885A (OSRAM) |
| KR (1) | KR20030034161A (OSRAM) |
| CN (1) | CN100384837C (OSRAM) |
| AR (1) | AR033680A1 (OSRAM) |
| AT (1) | ATE359281T1 (OSRAM) |
| AU (2) | AU8845101A (OSRAM) |
| BR (1) | BR0113675A (OSRAM) |
| CA (1) | CA2420673A1 (OSRAM) |
| CO (1) | CO5640109A2 (OSRAM) |
| DE (1) | DE60127846T2 (OSRAM) |
| EC (1) | ECSP034494A (OSRAM) |
| ES (1) | ES2284686T3 (OSRAM) |
| HK (1) | HK1054548B (OSRAM) |
| HU (1) | HUP0302942A3 (OSRAM) |
| IL (1) | IL154528A0 (OSRAM) |
| MX (1) | MXPA03001849A (OSRAM) |
| NO (1) | NO20030918L (OSRAM) |
| NZ (1) | NZ524246A (OSRAM) |
| PE (1) | PE20020486A1 (OSRAM) |
| PL (1) | PL361103A1 (OSRAM) |
| RU (1) | RU2293734C9 (OSRAM) |
| SK (1) | SK2292003A3 (OSRAM) |
| TW (1) | TWI268280B (OSRAM) |
| WO (1) | WO2002018368A1 (OSRAM) |
| ZA (1) | ZA200301545B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) * | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| CA2440555A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| EP1435959A2 (en) * | 2001-10-09 | 2004-07-14 | University of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| HUP0402401A2 (hu) * | 2001-11-30 | 2005-03-29 | Schering Corp. | Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| CA2520172C (en) * | 2003-03-27 | 2012-10-02 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor |
| WO2005000230A2 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
| WO2005001053A2 (en) * | 2003-06-09 | 2005-01-06 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist |
| ES2235611B2 (es) * | 2003-07-25 | 2006-07-16 | Universidade De Santiago De Compostela | Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas. |
| ATE417041T1 (de) * | 2003-08-07 | 2008-12-15 | Schering Corp | Neue farnesylproteintransferaseinhibitoren als antitumormittel |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| AU2005319182A1 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
| RU2361587C1 (ru) * | 2008-02-14 | 2009-07-20 | Михаил Владимирович Кутушов | Лекарственное средство для лечения онкологических заболеваний |
| WO2010006432A1 (en) * | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| WO2020258211A1 (en) * | 2019-06-28 | 2020-12-30 | Anhui Ronghang Biotech Development Co., Ltd. | Compositions and methods for treatment of hepatitis b virus infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| ZA914764B (en) * | 1990-06-22 | 1992-03-25 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| PE92098A1 (es) * | 1996-07-31 | 1998-12-31 | Schering Corp | N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| ATE293622T1 (de) * | 1998-12-18 | 2005-05-15 | Schering Corp | Farnesyl protein transferase inhibitoren |
-
2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Ceased
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en not_active Ceased
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 PL PL01361103A patent/PL361103A1/xx unknown
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 HK HK03105016.6A patent/HK1054548B/en not_active IP Right Cessation
-
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI268280B (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| BRPI0418031A (pt) | inibidores de quinase fosfonato-substituìdos | |
| BR0206955A (pt) | Ligantes de receptores de canabinóides | |
| BR0308261A (pt) | Métodos extrativos para puruficação de sucralose | |
| BR0308071A (pt) | Inibidores da protéina farnesil transferase como agentes antitumores | |
| BR0113234A (pt) | Polimorfos de um análogo de epotilona | |
| ATE206390T1 (de) | Cyclobutan-derivate als inhibitoren der squalen- synthase und der protein farnesyltransferase | |
| WO2002068406A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| GT200400133AA (es) | Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133). | |
| BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
| SE0302192D0 (sv) | Novel compounds | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| JOP20250215A1 (ar) | ثيازولو[4،5-d]-بيريميدين-7-ونات كمثبطات NOX4 | |
| ZA202212150B (en) | Tricyclic compounds as egfr inhibitors | |
| BRPI0413384A (pt) | inibidores da proteìna farnesil transferase como agentes antitumores | |
| ATE238981T1 (de) | Antitumorwirkstoffe | |
| Lone et al. | Synthesis and biological evaluation of amino analogs of Ludartin: potent and selective cytotoxic agents | |
| BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
| MXPA04000531A (es) | Acilsemicarbazidas como inhibidores de cinasa dependiente de ciclina utiles como agentes anti-cancer y anti-proliferativos. | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| MX2009002998A (es) | Derivado de pirazolopirimidina. | |
| MXPA05011289A (es) | Compuestos de fosfato que tienen actividad inmunomoduladora. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (US) , PHARMACOPEIA DRUG DISC Free format text: TRANSFERIDO DE: PHARMACOPEIA, INC. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |